[go: up one dir, main page]

SG11201808994YA - Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof - Google Patents

Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof

Info

Publication number
SG11201808994YA
SG11201808994YA SG11201808994YA SG11201808994YA SG11201808994YA SG 11201808994Y A SG11201808994Y A SG 11201808994YA SG 11201808994Y A SG11201808994Y A SG 11201808994YA SG 11201808994Y A SG11201808994Y A SG 11201808994YA SG 11201808994Y A SG11201808994Y A SG 11201808994YA
Authority
SG
Singapore
Prior art keywords
flag
international
antibodies
chain variable
axl
Prior art date
Application number
SG11201808994YA
Inventor
Jay M Short
Hwai Wen Chang
Gerhard Frey
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of SG11201808994YA publication Critical patent/SG11201808994YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111111011111111011111011111101111011111 International Bureau ... .1 j ..... .....!;,,, (10) International Publication Number (43) International Publication Date WO 2017/180842 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07K 16/28 (2006.01) G01N 33/68 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 47/50 (2017.01) A61K 39/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US2017/027372 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 13 April 2017 (13.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/323,036 15 April 2016 (15.04.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: BIOATLA, LLC [US/US]; 11011 Torreyana TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Road, San Diego, CA 92121 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: SHORT, Jay M.; 12985 Via Esperia, Del mar, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, California 92014 (US). CHANG, Hwai Wen; 1318 Shad- ow Hills Drive, San Marcos, California 92069 (US). GW, KM, ML, MR, NE, SN, TD, TG). FREY, Gerhard; 13768 Via Cima Bella, San Diego, Cali- Declarations under Rule 4.17: _ fornia 92129 (US). — of inventorship (Rule 4.17(N)) (74) Agent: DUNLEAVY, Kevin J.; MENDELSOHN DUN- Published: = LEAVY, P.C., 1500 John F. Kennedy Blvd., Suite 312, = Philadelphia, Pennsylvania 19102 (US). — with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every — with sequence listing part of description (Rule 5.2(a)) = kind of national protection available): AE, AG, AL, AM, = = (54) Title: ANTI-AXL ANTIBODIES, OF = 3 ng 75 inAb = 1.5 = = t a. 11 .4 ei 71' __ ot b ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES 75 fig rrAbIlh 0 ill_ ! = 60 °C 10 ng mAb 10 ng mAbilh il 1 MIMI 0 _214 et74 = ' —PAL-_ AND USES THERE- 60 °C !Mut $ GC © QC There are 11 antibodies tester under each condition (i.e., 11 bars in each set of bars). The 11 bars under each condition from left to right represent respectively clones BAP063 10F10, BAP063.9-13-1-FIAG, BAP063.9-29-2-FLAG, BAPC63.9-45-2-FIAG, BAN/63.9-13-3- FLAG, BAP063 21 3 FLAG, BAP063.9-21-4-FLAG, BAP063.9-29-4-FLAG, BAP063.9-48-3-FLAG. non-specific rhAh, no mAh 11 FIG. 5 N 11 0 (57) : A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl \" protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable re - Cgion that bind to Axl protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody frag- ments containing the polypeptide are also provided.
SG11201808994YA 2016-04-15 2017-04-13 Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof SG11201808994YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662323036P 2016-04-15 2016-04-15
PCT/US2017/027372 WO2017180842A1 (en) 2016-04-15 2017-04-13 Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11201808994YA true SG11201808994YA (en) 2018-11-29

Family

ID=60042774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808994YA SG11201808994YA (en) 2016-04-15 2017-04-13 Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof

Country Status (12)

Country Link
US (3) US11149088B2 (en)
EP (2) EP4656204A2 (en)
JP (5) JP6735355B2 (en)
KR (5) KR20200087875A (en)
CN (1) CN109563164A (en)
AU (4) AU2017248644B2 (en)
CA (1) CA3021086C (en)
IL (1) IL262173B (en)
MX (3) MX395074B (en)
SG (1) SG11201808994YA (en)
TW (3) TWI844893B (en)
WO (1) WO2017180842A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542332B2 (en) * 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109563164A (en) * 2016-04-15 2019-04-02 生物蛋白有限公司 Anti-AXL antibodies, antibody fragment and their immunoconjugates with and application thereof
MX394735B (en) 2016-05-13 2025-03-24 Bioatla Llc ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND THEIR USES.
JP2019528323A (en) 2016-08-31 2019-10-10 バイオアトラ、エルエルシー Conditionally active polypeptide and method for producing the same
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
CN107759691B (en) * 2017-12-04 2018-09-25 杭州尚健生物技术有限公司 A kind of monoclonal antibody of specific binding AXL
CN110483639A (en) 2018-05-15 2019-11-22 复旦大学 Target antibody and the antibody-drug conjugates and its preparation method and application of AXL
CN110540592B (en) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 Antibodies that bind to AXL protein and uses thereof
CA3103414A1 (en) 2018-06-14 2019-12-19 Bioatla, Inc. Multi-specific antibody constructs
JP7432250B2 (en) * 2018-09-07 2024-02-16 バイオアトラ インコーポレイテッド Conditionally activated chimeric antigen receptor for modified T cells
US20220177593A1 (en) * 2019-03-29 2022-06-09 Celldex Therapeutics, Inc. Anti-axl antibodies and methods of use thereof
WO2021013746A1 (en) 2019-07-19 2021-01-28 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
AU2021377224A1 (en) * 2020-11-12 2023-06-22 Bioatla, Inc. Methods of treating axl-expressing cancers with anti-axl antibodies, antibody fragments and their immunoconjugates
JP2024523436A (en) * 2021-06-16 2024-06-28 上海▲シン▼湾生物科技有限公司 Antibodies targeting AXL protein and antigen-binding fragments thereof, methods for their preparation and use
CN116348497B (en) * 2023-01-05 2023-11-17 浙江时迈药业有限公司 Antibodies against AXL and uses thereof
CN121263445A (en) * 2023-06-06 2026-01-02 拜奥卡德联合股份公司 Monoclonal antibodies or antigen-binding fragments thereof that specifically bind to AXL and uses thereof
WO2025198961A1 (en) * 2024-03-19 2025-09-25 BioAtla, Inc Methods and pharmaceutical composition for the treatment of adenoid cystic carcinoma

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI102355B1 (en) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Process for Preparation of Anthracycline Immunoconjugates with a Linking Link
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FI941572A7 (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES
JP3714970B2 (en) 1998-03-26 2005-11-09 アステラス製薬株式会社 Sustained release formulation
DK1068241T3 (en) 1998-04-02 2008-02-04 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
EP1413582B1 (en) 1998-08-27 2006-03-15 Spirogen Limited Dimeric pyrrolobenzodiazepines
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MX353234B (en) 1999-01-15 2018-01-08 Genentech Inc Polypeptide variants with altered effector function.
DK1176195T3 (en) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
WO2001029246A1 (en) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EA013224B1 (en) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
DE60336548D1 (en) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP FUCOSET TRANSPORT
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
BR0309145A (en) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Cells from which the genome is modified
JPWO2003085119A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
PT2357006E (en) 2002-07-31 2016-01-22 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP2006500364A (en) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド Crosslinkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20100366A (en) 2002-12-16 2011-04-30 Genentech, Inc. Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk HYBRID PROTEIN COMPOSITION
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
WO2005040170A2 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
HUE042914T2 (en) 2003-11-05 2019-07-29 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0516284A (en) 2004-09-23 2008-09-02 Genentech Inc cysteine-constructed antibody, method of selecting antibodies, drug-antibody conjugated compounds, pharmaceutical composition, method for killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, manufactured article and method to produce a compound
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP2722051B1 (en) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PT1813614E (en) 2006-01-25 2012-01-09 Sanofi Sa Cytotoxic agents comprising new tomaymycin derivatives
CA2658276A1 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody for the treatment of cancer
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2435779T3 (en) 2007-07-19 2013-12-23 Sanofi Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use
MY155621A (en) 2007-11-12 2015-11-13 U3 Pharma Gmbh Axl antibodies
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
ES2547552T3 (en) 2008-02-01 2015-10-07 Genentech, Inc. Nemorubicin metabolite and similar reagents, antibody-drug conjugates and methods
SG192517A1 (en) 2008-07-15 2013-08-30 Genentech Inc Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EP2406399B1 (en) 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
BRPI1013428A2 (en) * 2009-05-11 2019-07-02 U3 Pharma Gmbh humanized antibodies to axl
DE102009022019A1 (en) 2009-05-15 2010-11-18 Siemens Aktiengesellschaft Arrangement with a position sensor detecting the position of a mechanical moving part
WO2011008517A2 (en) * 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
TWI540136B (en) 2010-04-15 2016-07-01 梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
CA2810668A1 (en) * 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
CN105189552B (en) 2013-03-14 2019-08-02 基因泰克公司 Anti-B7-H4 Antibodies and Immunoconjugates
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
DK3169706T3 (en) * 2014-07-11 2020-03-09 Genmab As ANTIBODIES THAT BINDER AXL
DK4074735T3 (en) 2014-08-28 2025-07-14 Bioatla Inc CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
US11111288B2 (en) * 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
IL261713B2 (en) 2016-03-19 2023-09-01 F1 Oncology Inc Methods and compositions for transducing lymphocytes and regulated expansion thereof
CN109563164A (en) * 2016-04-15 2019-04-02 生物蛋白有限公司 Anti-AXL antibodies, antibody fragment and their immunoconjugates with and application thereof

Also Published As

Publication number Publication date
JP7456658B2 (en) 2024-03-27
AU2020200324A1 (en) 2020-02-06
KR20230162730A (en) 2023-11-28
KR20210110740A (en) 2021-09-08
MX395074B (en) 2025-03-24
KR20220141910A (en) 2022-10-20
AU2022203222B2 (en) 2025-05-15
IL262173B (en) 2021-06-30
KR102606938B1 (en) 2023-11-29
TW201833138A (en) 2018-09-16
EP3443012B1 (en) 2025-11-19
JP6735355B2 (en) 2020-08-05
EP3443012A1 (en) 2019-02-20
IL262173A (en) 2018-11-29
TW202423988A (en) 2024-06-16
KR102697688B1 (en) 2024-08-21
CA3021086C (en) 2023-10-17
CN109563164A (en) 2019-04-02
EP3443012A4 (en) 2019-09-11
US11149088B2 (en) 2021-10-19
JP2023011607A (en) 2023-01-24
AU2020200324B2 (en) 2022-02-24
TWI844893B (en) 2024-06-11
US20240199746A1 (en) 2024-06-20
JP2026017554A (en) 2026-02-04
JP7759130B2 (en) 2025-10-23
JP2020180152A (en) 2020-11-05
EP4656204A2 (en) 2025-12-03
US20190177417A1 (en) 2019-06-13
US20210403577A1 (en) 2021-12-30
AU2017248644A1 (en) 2018-10-25
MX2022010487A (en) 2022-09-21
MX2022006461A (en) 2022-09-09
JP2019513784A (en) 2019-05-30
JP7161783B2 (en) 2022-10-27
TW202246348A (en) 2022-12-01
KR20180126079A (en) 2018-11-26
AU2025205498A1 (en) 2025-08-14
AU2022203222A1 (en) 2022-06-02
MX2018012418A (en) 2019-07-10
WO2017180842A1 (en) 2017-10-19
KR20200087875A (en) 2020-07-21
US11897959B2 (en) 2024-02-13
EP3443012C0 (en) 2025-11-19
JP2024088638A (en) 2024-07-02
CA3021086A1 (en) 2017-10-19
TWI771297B (en) 2022-07-21
AU2017248644B2 (en) 2019-10-31
KR102459684B1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
SG11201808994YA (en) Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
SG11201808882QA (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810883TA (en) Combination therapy
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function